Showing 82,921 - 82,940 results of 226,904 for search '(( a ((a decrease) OR (we decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 2.23s Refine Results
  1. 82921
  2. 82922
  3. 82923
  4. 82924
  5. 82925

    Heterogeneity analysis. by Ying Zhao (16546)

    Published 2025
    “…However, current cross-sectional studies have only demonstrated an association, failing to establish a causal link. Therefore, a comprehensive investigation is necessary to clarify the causal relationship between them. …”
  6. 82926

    Reverse MR analysis data. by Ying Zhao (16546)

    Published 2025
    “…However, current cross-sectional studies have only demonstrated an association, failing to establish a causal link. Therefore, a comprehensive investigation is necessary to clarify the causal relationship between them. …”
  7. 82927

    SNP dressing by screening. by Ying Zhao (16546)

    Published 2025
    “…However, current cross-sectional studies have only demonstrated an association, failing to establish a causal link. Therefore, a comprehensive investigation is necessary to clarify the causal relationship between them. …”
  8. 82928

    Electroretinogram (ERG) recordings from 6-, 9-, and 12-month mice show deficits in 5xFAD photoreceptors. by Shaylah McCool (20818280)

    Published 2025
    “…Two-way ANOVA with Tukey’s multiple comparisons post-hoc test was used for analysis. (C) Quantification of A- and B-wave amplitudes at the highest intensity stimulus (3.0000 cd * s/m<sup>2</sup>) shows the significant increase and decrease in retinal function in the 6- and 9-month 5xFAD mice, respectively, analyzed by two-way ANOVA with Tukey’s multiple comparisons. …”
  9. 82929
  10. 82930
  11. 82931
  12. 82932
  13. 82933
  14. 82934

    Table_1_Efficiency trends of essential public health services and possible influencing factors since the new round health reform in China: a case study from Hainan Province.DOCX by Ye Tian (220278)

    Published 2023
    “…</p>Conclusion<p>There was a short-term improvement in the efficiency of EPHS in Hainan after the launch of the new round of health reform. …”
  15. 82935

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Results: In base case analysis, cemiplimab compared with pembrolizumab was associated with a gain of 0.44 quality-adjusted life-years (QALYs) and an increased cost of $23,084, resulting in an incremental cost-effectiveness ratio (ICER) of $52,998/QALY; cemiplimab compared with atezolizumab was associated with a gain of 0.13 QALYs and a decreased cost of $104,642, resulting in its dominance of atezolizumab. …”
  16. 82936

    Image1_Hip-Preserved Reconstruction Using a Customized Cementless Intercalary Endoprosthesis With an Intra-Neck Curved Stem in Patients With an Ultrashort Proximal Femur: Midterm F... by Qi You (492233)

    Published 2022
    “…</p><p>Conclusion: The CCIE with an INCS was a valid and reliable method for reconstructing femoral diaphyseal defects with a UPF following malignant tumor resection. …”
  17. 82937

    Table1_Augmenting mesenchymal stem cell therapy for osteoarthritis via inflammatory priming: a comparative study on mesenchymal stem cells derived from various perinatal tissue sou... by Xinzi Xia (17090581)

    Published 2023
    “…<p>Background: Osteoarthritis (OA), a degenerative disease prevalent among the elderly, poses significant challenges due to its high incidence and disability rates. …”
  18. 82938

    Image2_Hip-Preserved Reconstruction Using a Customized Cementless Intercalary Endoprosthesis With an Intra-Neck Curved Stem in Patients With an Ultrashort Proximal Femur: Midterm F... by Qi You (492233)

    Published 2022
    “…</p><p>Conclusion: The CCIE with an INCS was a valid and reliable method for reconstructing femoral diaphyseal defects with a UPF following malignant tumor resection. …”
  19. 82939

    DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Results: In base case analysis, cemiplimab compared with pembrolizumab was associated with a gain of 0.44 quality-adjusted life-years (QALYs) and an increased cost of $23,084, resulting in an incremental cost-effectiveness ratio (ICER) of $52,998/QALY; cemiplimab compared with atezolizumab was associated with a gain of 0.13 QALYs and a decreased cost of $104,642, resulting in its dominance of atezolizumab. …”
  20. 82940

    DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Results: In base case analysis, cemiplimab compared with pembrolizumab was associated with a gain of 0.44 quality-adjusted life-years (QALYs) and an increased cost of $23,084, resulting in an incremental cost-effectiveness ratio (ICER) of $52,998/QALY; cemiplimab compared with atezolizumab was associated with a gain of 0.13 QALYs and a decreased cost of $104,642, resulting in its dominance of atezolizumab. …”